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Aim: To review the treatment results and identify prognostic factors for disease control
and survival in a cohort of nasopharyngeal carcinoma (NPC) patients from a non-endemic
population in Slovenia, diagnosed between 1990 and 2003.
Background: In Caucasians, nasopharyngeal carcinoma is a rare malignant tumor. Its diagno-
sis  and treatment are complex and have been dramatically impacted by recent technological
advances.
Materials and methods: In the Cancer Registry of Slovenia database, a total of 126 patients
with  NPC were identiﬁed, 93 of whom were available for analysis. All patients were treated
with  conventional two-dimensional radiotherapy (RT) and 29.3% underwent chemotherapy
(ChT).
Results: The median follow-up time for those alive at the last follow-up examination was 74.5
months. Disease recurred locally in 17 patients, regionally in 4 patients and at distant sites in
18  patients, resulting in 5-year locoregional control (LRC), distant failure-free survival (DFFS)
and  disease-free survival (DFS) of 73.7%, 78.6% and 59.3%, respectively. Disease-speciﬁc sur-
vival at 5 years was 59% and overall survival (OS) was 49.7%. In a multivariate analysis, LRC
was  favorably affected (P < 0.05) by an undifferentiated histology (hazard ratio [HR] = 2.86),
DFFS through the absence of neck metastases (HR = 0.28), DFS by younger age (HR = 0.46), and
more  intensive RT (expressed as the isoeffective dose, EQD2,T; HR = 2.08). The independent
prognosticator for OS was age (≤55 years vs. >55 years, HR = 0.39); in the ≤55 years subgroup,
an improved OS was connected to a more intensive RT regimen of EQD2,T ≥ 66 Gy (HR = 4.17).
Conclusions: Our results conﬁrm an independent and favorable effect from an undifferen-
tiated histology, the absence of neck metastases, a younger patient age at diagnosis, and
more intensive RT regimens for disease control and survival.
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Table 1 – Characteristics of patients and their tumors.
Patients (N = 93)
Sex (female/male) 28/65
Age 55 (20–86)a
UICC TNM-classiﬁcation
(2002)
N0 N1 N2 N3 Total
TX 0 1 0 0 1
T1 6 12 10 6 34
T2 8 9 3 1  21
T3 7 0 3  1 11
T4 15 4 2 5 26
Total 36 26 18 13 93
Overall stage
Stage I 6 (6.5%)
Stage IIA 6 (6.5%)
Stage IIB 23 (24.7)
Stage III 23 (24.7)
Stage IVA 21 (22.6%)
Stage IVB 14 (15.1%)
Histology
WHO I 4 (4.3%)
WHO II 20 (21.5%)
WHO III 68 (73.1%)
Other 1 (1.1%)
Diagnostic CT/MRI 71 (76.3%)
Chemotherapy 21 (22.6%)
UICC, International Union Against Cancer; WHO, World Health
Organization; CT, computed tomography; MR, magnetic resonance.72  reports of practical oncology a
1.  Background
Nasopharyngeal carcinoma (NPC) is a rare malignant tumor
which appears sporadically in Slovenia and most parts of the
Western world.1 According to the National Cancer Registry
of Slovenia, during the period 1990–2003 the annual inci-
dence of nasopharyngeal cancer was 0.75/100,000 males and
0.32/100,000 females.2 Multiple etiological factors were sug-
gested to contribute to the increased incidence of the disease,
including diet, viral agents and genetic susceptibility. The
symptoms and signs of nasopharyngeal carcinoma are non-
speciﬁc; furthermore, the nasal part of the pharynx is difﬁcult
to access for an unskilled examiner, which is why a substan-
tial proportion of the patients at the time of diagnosis already
displayed advanced stages of the disease.1
Modern imaging techniques, including computer tomog-
raphy (CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET) allow for the recognition of disease
extensions that are not visible at clinical examination. They
have dramatically impacted the radiotherapy (RT) procedures
and techniques used in NPC which is the main treatment
modality for this disease. Chemotherapy (ChT) has a role
to play in advanced stages of the disease, whereas up-front
surgery is rarely used in NPC due to the complexity of the
anatomical relationship with adjacent structures and related
morbidity.3
2.  Aim
The majority of studies carried out on NPC have been con-
ducted in endemic countries. Therefore, the present analysis
of the retrospective series of NPC patients diagnosed and
treated in Slovenia between 1990 and 2003 may highlight the
range of conventional two-dimensional RT in the treatment of
this rare disease in non-endemic areas. The secondary aim of
the study was to identify prognostic factors for disease control
and survival.
3.  Materials  and  methods
3.1.  Patient  and  disease  characteristics
Between 1990 and 2003, a total of 126 patients with NPC were
registered in the National Cancer Registry database.2 Patients
less than 16 years of age (who entered pediatric treatment
protocols, 5), those with no therapy or treated with palliative
intent (15), patients with a primary tumor originating outside
the nasopharynx (found in the clinical chart review, 9), and
those with incomplete documentation (3) or recurrent disease
(1) were excluded. A total of 93 patients treated with curative
intent left for detailed analysis. In this group, the median age
and the ratio between sexes was 55 years (average 53.8 years,
range 20–86 years) and 2.3:1 (65 males vs. 28 females), respec-
tively. Details on the characteristics of the patients and tumors
are shown in Table 1.
The median time to elapse from the onset of the ﬁrst symp-
tom or sign to the histological conﬁrmation of the disease was
3 months (range 0–24 months): this interval was 3–6 monthsa Median (range), in years.
in 24 patients (25.8%), 6–12 months in 13 (14%) and over a year
in 6 patients (6.5%). The most common symptom was a palpa-
ble mass in the neck (48.4%), followed by nasal obstruction
or a persistent/bloody nasal discharge (18.3%), hearing loss
or otalgia (10.8%), headache (9.7%), neurological (7.5%) and
pharyngeal symptoms (sore throat, dysphagia; 2.2%). In three
patients (3.2%), the disease was discovered by chance. Upon
initial examination, cranial nerve involvement was found in
20 patients (21.5%). The most frequently involved cranial nerve
was n.V (14), followed by n.VI (6), nn.III, IX and X (in 5 patients
each), n.XII (4), n.VII (3), n.IV (2) and n.VIII (1). Ten patients
had isolated nerve dysfunction and ten patients had multiple
cranial nerve involvement.
All patients underwent an endoscopy with a biopsy, a com-
plete blood count and blood chemistry proﬁles with liver and
renal function tests, a chest X-ray or CT, and ultrasonogra-
phy of the abdomen, whereas other examinations (e.g. a bone
scan) were conducted if clinically indicated. A pre-treatment
diagnostic CT, MRI or both of the nasopharynx and the neck
were carried out in 68 (73.1%), 1 and 2 of the patients, respec-
tively. PET was not yet available in Slovenia at that time.
Using the World Health Organization’s (WHO) histological
classiﬁcation of NPC,4 68 (73.1%) patients had undifferentiated
carcinoma (WHO type III), whereas nonkeratinizing carcinoma
(WHO type II) and squamous cell carcinoma (WHO type I)
were present in 20 (21.5%) and 4 (4.3%) patients, respectively;
one patient had spindle cell carcinoma. All patients were ret-
rospectively re-staged for the purpose of the present study
according to the International Union Against Cancer (UICC)
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002 staging system.5 As a result, the majority of patients were
ound to have advanced-stage disease: I – 6 (6.5%), IIA – 6 (6.5%),
IB – 23 (24.7%), III – 23 (24.7%), IVA – 21 (22.6%) and IVB – 14
15.1%).
.2.  Treatment
.2.1. Radiotherapy
ll patients were irradiated with cobalt-60 (46, 49.5%) or
inear accelerator (47, 50.5%) 5–8 MV  photon beams and a
onventional 3-ﬁeld technique using two-dimensional com-
uter planning, head holders with thermoplastic casts and
ndividual shielding blocks. The median daily dose was 2 Gy
range 1.8–3 Gy; >2 Gy in 3 patients) applied in one fraction, ﬁve
imes per week, as speciﬁed on the 100% isodose curve. The
edian total dose to the gross tumor volume was 70 Gy (range
1–75.5 Gy, >60 Gy in 95.7%). The gross tumor volume and a
argin of 1.5–2 cm was within at least the 95% isodose curve
nd, to achieve dose homogeneity within a range of ±5% inside
he treated volume, wedge ﬁlters and tissue compensation
oluses were used when appropriate. Clinically uninvolved
ymphatic drainage basins on the neck received 50 Gy and the
pinal cord was shielded after a dose of 46 Gy. After off-cord
hoton ﬁeld reduction, the dose to the posterior lymph node
riangle was supplemented with electron beams of appropri-
te energy (9–12 MeV) to the prescribed dose level. Portal ﬁlms
ere obtained at the beginning of the RT course and whenever
 change of technique occurred.
Since the overall treatment time differed signiﬁcantly
mong the patients (median 53 days, range 40–84 days), the
soeffective dose (EQD2,T) was calculated to compare the inten-
ity of the different radiotherapy regimens employed using the
ollowing formula:
QT2,T = EQD2,t − (T − t) × Dprolif
here EQD2 is the equivalent total dose in 2 Gy fractions (Gy); T
s the actual overall treatment time (in days); t is the expected
verall treatment time (47 days); Dprolif is the dose recovered
er day due to proliferation (0.7 Gy/day).6 When consider-
ng the actual duration of the RT course in our patients, the
edian EQD2,T was 65 Gy (range 47–71.4 Gy; >60 Gy in 74.2%).
.2.2.  Chemotherapy
n 21 (22.6%) patients, chemotherapeutics were adminis-
ered concurrently with RT. During RT, all but one patient
ere administered cisplatin (100 mg/m2 I.V. in 3-week inter-
als) which was combined in one patient with 5-ﬂuorouracil
1000 mg/m2 I.V. days 1–4). One patient had a combination of
itomycin C (15 mg/m2 I.V. at 10 Gy of RT) and bleomycin (5 mg
.M. twice per week). The median number of concurrent ChT
dministrations was 2 (range 1–3 cycles).
Adjuvantly, various combinations of cisplatin (100 mg/m2,
ay 1), carboplatin (AUC 6, day 1) and 5-ﬂuorouracil
1000 mg/m2, days 1–5) were administered at 3-week intervals
n 7 (7.5%) patients (all also underwent concomitant ChT). The
edian number of adjuvant ChT cycles was 3 (range 1–3)..2.3. Surgery
even patients (7.5%) underwent surgical resection. One
atient had a partial resection of the primary tumor foriotherapy 1 7 ( 2 0 1 2 ) 71–78 73
diagnostic purposes. Prior to initiation and after completion
of the RT (for residual disease), a neck dissection was carried
out in two and four patients, respectively. In the latter group,
malignant cells were found in two out of the four cases.
3.3.  Statistics
The statistical analysis was performed using the PC SPSS
(Release 13.0, SPSS Inc., Chicago, IL) statistical package. A uni-
variate analysis of patients’ survival was carried out using
the Kaplan–Meier product-limit method with 95% conﬁdence
intervals (CI) reported7 and the differences between poten-
tial prognostic subgroups were tested for signiﬁcance using
the log-rank test.8 To identify independent prognostic factors
for disease control and survival, a multivariate analysis was
performed with the Cox regression model.9 All of the tests
were two-sided, and the results were considered signiﬁcant at
a probability level of ≤5%.
Survival times were calculated from the date of histolog-
ical conﬁrmation of the disease. Persistence of the disease
for more  than three months post-therapy or progression fol-
lowing a complete response after (ChT)RT or unsuccessful
surgery (if performed) with residual disease left behind and
distant metastases was deﬁned as a failure. The endpoints
of the survival analysis were local (LC), regional (RC) and
locoregional control (LRC) (persistent disease or recurrence
in the nasopharynx, in the neck or in both sites, respec-
tively, is considered as an event), distant failure-free survival
(DFFS, the appearance of systemic metastases considered as
an event), disease-free survival (DFS, persistent/recurrent dis-
ease locally, regionally and/or at distant sites considered as
an event), disease-speciﬁc survival (DSS, death due to disease
considered as an event), and overall survival (OS, death of
whatever cause considered as an event).
4.  Results
The median follow-up time for all patients was 38 months
(range 1–181 months) and was 74.5 months (range 5–181
months) in those alive at the most recent follow-up exami-
nation.
4.1.  Pattern  of  treatment  failure
Treatment failed locally in 17 (18.3%) patients within an inter-
val of 0–35 months (median 12 months). LC at 5 years was
78.4% (95% CI 69.1–87.6). Four patients failed in the neck, all
with primary controlled, 5–14 months (median 9.5 months)
after diagnosing NPC, resulting in RC at 5 years of 95% (95%
CI 90.3–99.8). The LRC at 5 years was 73.7% (95% CI 63.9–83.5)
(Fig. 1).
A total of 18 patients (19.3%) developed distant metastases,
resulting in a 5-year DFFS of 78.6% (95% CI 69.5–87.7) (Fig. 1).
The median time for the occurrence of systemic disease was
19.8 months (range 6–60 months; ≤3 years in 16 patients) with
the most frequently affected sites being the bone (10), liver
(3) and lymph nodes below the clavicles (3), followed by lung
and subcutis (in one patient each). Distant metastases were
the ﬁrst sign of disease progression in 13 patients, whereas 5
74  reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 71–78
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Fig. 2 – Patients ≤55 years of age: effect of intensity of
radiotherapy (EQD2,T): A, disease-free survival; B, overall
survival.Fig. 1 – Local, regional and distant control.
patients experienced distant failure after regional (3) or local
failure (2). The DFS at 5 years for all 93 patients was 59.3% (95%
CI 48.7–69.9) (Fig. 1).
Upon a multivariate analysis, only histology was identiﬁed
as an independent prognostic factor for LRC with an undiffer-
entiated variant favorably affecting prognosis when compared
to nonkeratinizing tumors (p = 0.02, hazard ratio [HR] = 2.68,
95% CI 1.16–7.14). With regard to DFFS, N0-neck was con-
ﬁrmed as an independent and positive prognosticator (N0 vs.
N+: p = 0.045, HR = 0.28, 95% CI 0.08–0.97). DFS was found to be
better for younger patients (≤55 years vs. >55 years: p = 0.027,
HR = 0.46, 95% CI 0.23–0.92) and for those irradiated with higher
EQD2,T (<64 Gy vs. ≥64 Gy: p = 0.037, HR = 2.08, 95% CI 1.04–4.17)
(Table 2). In patients aged ≤55 years, a higher EQD2,T (<64 Gy
vs. ≥64 Gy: p = 0.035, HR = 3.45, 95% CI 1.09–11.11) and undif-
ferentiated histology (nonkeratinizing vs. undifferentiated:
p = 0.002, HR = 5.55, 95% CI 1.82–16.67) favorably affected DFS
in a multivariate analysis (Fig. 2A).
4.2. Salvage  therapy  and  outcome
A total of 13 out of the 17 (76.5%) patients with local failure
and 3 out of the 4 patients with regional failure had salvage
therapy. Tele-RT was used in 12 locally recurrent cases and
adjuvant to surgery in one case with a neck recurrence (the
Table 2 – Results of multivariate analysis for various
endpoints.
Endpoint Independent
prognostic factor(s)
p-Value HR (95% CI)
LRC Histology: WHO type II
vs. III
0.02  2.86 (1.16–7.14)
DFFS N stage: N0 vs. N+ 0.045 0.28 (0.08–0.97)
DFS Age: ≤55 years vs. >55
years
0.027 0.46 (0.23–0.92)
EQD2,T: <64 Gy vs.
≥64 Gy
0.037  2.08 (1.04–4.17)
OS Age (years): ≤ 55 vs. >55 0.001 0.39 (0.23–0.68)
LRC, loco-regional control; DFFS, distant failure-free survival; DFS,
disease-free survival; OS, overall survival; EQD2,T, equivalent tumor
dose; HR, hazard ratio; CI, conﬁdence interval.other two patients had neck dissections); one patient with
local failure had multi-agent platinum-based chemotherapy
(Fig. 3). The median EQD2 of the salvage tele-RT was 30.8 Gy
(range 24.8–56 Gy). In three patients with local failure who
had tele-RT combined with Ir-192 low-dose-rate brachyther-
apy application, the cumulative re-treatment doses were 44.6,
46.5 and 63.2 Gy with a complete response achieved in only
one case.
In re-treated patients, the median survival from the diag-
nosis of local or regional failure was 20 months (range 3–51
months) and 29 months (range 5–53 months). All but two of
the patients died of disease progression. One patient was still
alive 48 months after re-treatment and displayed no evidence
of the disease; the other died due to secondary primary lung
carcinoma but was free of NPC 11 months after salvage ther-
apy; both had recurrences at the primary site. The median
survival of the ﬁve untreated patients was ﬁve months (range
1–11 months); four of the patients died due to the progression
of NPC, and the ﬁfth one died of a new primary liver carcinoma.
A total of 16 out of 18 (88.9%) patients with distant metas-
tases had additional therapy: z had a combination of RT and
ChT, 5 patients had only ChT and 4 patients only RT. The
median survival after the occurrence of systemic disease was
5 months (range 0–15 months).
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 71–78 75
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Fig. 3 – Salvage therapy for disease recurrence and outcome.
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o.3.  Disease-speciﬁc  and  overall  survival
n the close-out date, a total of 38 (40.9%) patients were alive
ith no signs of NPC and 55 (59.1%) patients died: 36 (38.7%)
ied of NPC and 19 (20.4%) due to causes unrelated to the
isease. A secondary primary tumor developed in 14 (15.1%)
atients between a 0- and 53-month (median 20 months) post-
iagnosis of index NPC.
The 5-year DSS was 59% (95% CI 48.2–69.8) (Fig. 4). In a uni-ariate analysis, a statistically signiﬁcant effect of EQD2,T was
bserved in a subgroup of patients aged ≤55 years (<66 Gy vs.
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Fig. 4 – Disease-speciﬁc and overall survival.≥66 Gy: 55.4% vs. 89.5%, p = 0.026) but was not conﬁrmed in
multivariate testing (p = 0.075, HR = 0.25, 95% CI 0.05–1.15).
The OS at 5 years was 49.7% (95% CI 39.2–60.2) (Fig. 4). After
testing using the Cox model, a younger age was identiﬁed as
prognostically advantageous (≤55 years vs. >55 years; p = 0.001,
HR = 0.39, 95% CI 0.23–0.68) (Table 2). In the latter group, higher
EQD2,T (≥66 Gy) emerged as an independent and favorable
prognosticator over less intensive RT regimens (EQD2,T < 66 Gy;
p = 0.029, HR = 4.17, 95% CI 1.15–14.29) (Fig. 2B).
4.4.  Toxicity
Owing to the retrospective character of the present analysis, a
robust system was used for documentation of the treatment-
related complications collected from patients’ charts.
During concurrent ChT-RT with cisplatin, a transient pare-
sis of the peroneal nerve with foot drop occurred in one
patient. After therapy, there were 9/93 (.7%) cases of serious
side effects documented: dysfunction of the left cranial n.XII
(EQD2,T 5.6 Gy); retinopathy and optic nerve atrophy (EQD2,T
67.9 Gy with cisplatin-based concomitant ChT and one cycle
of adjuvant ChT); temporal lobe injury (EQD2,T 68 Gy, 70 Gy
and 127.3 Gy combined with concomitant and adjuvant ChT
in two  cases); necrotizing fasciitis (EQD2 124 Gy with concomi-
tant ChT during re-treatment); hearing loss (in 3 patients,
EQD2,T 63 Gy, 64.4 Gy and 69.1 Gy in combination with con-
comitant cisplatin: unilateral anacusis, bilateral conductive
and sensorineural hypoacusis, sensorineural on the right and
combined impairment on the left).
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Table 3 – Presenting symptoms and signs in patents with nasopharyngeal carcinoma reported in different studies.
Author (Ref.) Cervical mass
(%)
Cranial
nerve palsy
(%)
Nasal
symptoms
(%)
Ear
symptoms
(%)
Symptom Signa
Sanguineti et al. 10 41 79 8 21 27
Yi et al. 12 40.5 82.3 19.8 29 17
Hoppe et al. 15 44 71 12 29 28
Present study 48.4 61.3 21.5 18.3 10.8a Clinical sign after physical and imaging examination.
5.  Discussion
When comparing the treatment results in NPC among differ-
ent series reported in the literature, one should be aware of
(at least) three important factors: the geographical origin of
the population studied (the West vs. Asia), the time period
under evaluation (owing to the evolution of diagnostic and
therapeutic procedures over time), and whether the results
were generated in a retrospective, pattern of practice analy-
sis, or prospective/randomized study.1 The cohort of patients
presented was found to be representative in terms of their
age, sex and histological distribution when compared to other
reports from Western countries, with the exception of a some-
what different ratio between squamous cell carcinoma (4.3%;
expected to be up to 25%) and nonkeratinizing carcinoma
(21.5%; expected to be approximately 10%).4,10 In contrast, the
median age of patients reported in the Asian series is 5 years
lower and almost all had undifferentiated tumors.4,11–14
The most common symptom in our patients was a pal-
pable mass in the neck (48.4%) and the majority (62.4%) had
stage III–IV disease at the time of diagnosis, with cranial nerve
palsies recorded in 21.5%. These ﬁgures agree well with the
literature data (10, 12, 15; Table 3). However, only 6.5% of
the patients were diagnosed with a primary tumor conﬁned
to nasopharynx (stage T1) which pointed to the suboptimal
use of modern imaging techniques in diagnostics (76.3% of
patients had CT/MRI) and, as a result, too high a probability of
an inaccurately determined T-stage of the disease. Moreover,
in the early-stage disease group, the portion of radiologically
staged patients was signiﬁcantly lower than in the group
with advanced disease (54.3% vs. 89.3%; p = 0.0003, Fisher’s
exact test). Compared to similar surveys conducted after the
1990s with a diagnostic CT/MRI performed in virtually all the
patients,11,12,14,16 in our cohort pre-treatment evaluation was
suboptimal.
All our patients were treated with conventional 2D-RT and
with doses (the median EQD2,T was 65 Gy) usually imple-
mented in non-endemic areas. More  intensive RT with the
administration of a brachy- or tele-RT boost resulting in
cumulative doses well above 70 Gy was characteristic of RT
practice in Asian countries11–14,16 but also in some Western
RT centers.17,18 Nowadays, ChT is an integral component of all
curative treatment strategies in locoregionally advanced NPC,
and was administered in less than a quarter of our patients
(22.6%). Speciﬁcally, in the stage III-IV subgroup this percent-
age was 29.3 and before 1998, when a benchmark Intergroupstudy 0099 on the value of adding ChT to RT was published,19
only three patients from our series received ChT. In a com-
parison of the results on disease control and survival across
different studies from endemic and non-endemic regions
where 2D-RT was used,11–14,16,20 covering approximately the
same time span as that for our cohort, no striking differences
with our results were observed (Table 4). Somewhat supe-
rior ﬁgures for the selected endpoints seen in the individual
series should be valued in view of the lower median age of
patients treated,11–14,20 higher fraction of RT-sensitive undif-
ferentiated tumors,12,14,20 a more  consistent use of CT/MRI
in tumor staging11–14,16 or ChT,20 and, in particular, higher
cumulative RT doses11–14,16 and the use of 3D-conformal RT
techniques, including intensity-modulated RT (IMRT), in a
larger proportion of patients.14 Considering the retrospective
nature of these reports, including ours, it is very likely that the
incidence of treatment-related late toxicity recorded has been
underestimated and any detailed comparison of the results on
toxicity across different studies is questionable due to various
follow-up durations and detection systems implemented.
In the present series, the beneﬁcial effect of a younger
age at diagnosis, an undifferentiated histology, the absence of
neck metastases, and more  intensive RT regimens for disease
control and survival were observed in a multivariate analysis,
which is in line with other reports.10–14,16,20 Surprisingly, we
could not conﬁrm a prognostic signiﬁcance of modern imaging
techniques, T-stage, and ChT for any of the endpoints stud-
ied. As the distribution of patients with CT/MRI at diagnosis
differed signiﬁcantly between early and advanced stages of
the disease (T1, 54.3%; T2–4, 89.7%; p = 0.0003, Fisher’s exact
test), some patients from the early-stage group were very
likely to have more  advanced tumors. In addition, the risk
of geographical error is also increased if modern imaging is
not implemented consistently for the purpose of radiother-
apy planning, which resulted in control rates and survival
as poor as in the advanced-stage group. It is likely that the
understaging of some of the tumors led to the lack of prog-
nostic signiﬁcance of T-stage and ChT administration seen
among our patients. In fact, ChT was given more  frequently to
patients with more  advanced tumors (stage I–II, 11.4%; stage
II–IV, 29.3%; p = 0.046) although the proportion of combined
treatments in this group was also fairly low. Another reason
may be the low number of tumors of squamous cell histology
21which should, according to the meta-analysis of Bujaut et al.,
beneﬁt most from ChT.
What can we expect from a more  consistent use of
modern diagnostic imaging and systemic therapy, and from
reports of practical oncology and rad
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the implementation of 3D conformal RT techniques? An
evaluation of the locoregional extent of the disease with
MRI  was recognized as an independent prognostic factor
for the local control and survival of NPC patients from an
endemic area of Hong Kong.14 MRI  was found to cause
dramatic T- and clinical stage migrations (in about 50%
and 40% of cases, respectively) when compared to CT-
based staging that signiﬁcantly impacted the choice of
treatment strategies and the tumor target delineation for
RT.22,23 With 3D-planning, a highly conformal dose distribu-
tion with steep dose gradients is created, clearly superior to
2D-planning; further improvement in the locoregional con-
trol of the disease and toxicity proﬁle (including xerostomia
and quality of life testing) has been demonstrated with IMRT
in a number of dosimetric studies and conﬁrmed in ret-
rospective comparisons of RT techniques.16,24,25 Escalating
the dose to the primary by endocavitary brachytherapy or
stereotactic boost may further improve local control, although
at the expense of high incidence of late morbidity.11,12,17,18,26
Recently, the beneﬁcial effects of ChT administration, prefer-
ably concomitantly with irradiation, were conﬁrmed in several
meta-analyses.21,27
6.  Conclusions
The results presented conﬁrm the efﬁcacy (albeit far from
optimal) of conventional 2D-RT in curative treatment of NPC
patients from non-endemic areas, and an independent and
favorable effect of undifferentiated histology, absence of neck
metastases and younger patient age at diagnosis, and more
intensive RT regimens for disease control and survival. They
represent a good starting point when added value of modern
diagnostic and treatment methods, including ChT and IMRT,
is to be evaluated.
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